featured
Overall Survival Outcomes of Patients With Advanced EGFR-Mutant NSCLC Receiving Osimertinib vs Gefitinib Followed by Osimertinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
J. Clin. Oncol 2024 Feb 07;[EPub Ahead of Print], J Remon, B Besse, SP Aix, A Callejo, K Al-Rabi, R Bernabe, L Greillier, M Majem, N Reguart, I Monnet, S Cousin, P Garrido, G Robinet, RG Campelo, A Madroszyk, J Mazières, H Curcio, B Wasąg, Y Pretzenbacher, F Grillet, AC Dingemans, R DziadziuszkoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.